Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 16;3(3):77-82.
doi: 10.2991/chi.k.210403.001. eCollection 2021 Sep.

Therapeutic Use of Convalescent Plasma in COVID-19 Infected Patients with Concomitant Hematological Disorders

Francesco Lanza  1 , Vanessa Agostini  2 , Federica Monaco  1 , Francesco Passamonti  3 , Jerard Seghatchian  4
Affiliations
Review

Therapeutic Use of Convalescent Plasma in COVID-19 Infected Patients with Concomitant Hematological Disorders

Francesco Lanza et al. Clin Hematol Int. .

Abstract

The use of convalescent plasma (CP) from individuals recovered from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a promising therapeutic modality for the coronavirus disease 2019 (COVID-19). CP has been in use for at least a century to provide passive immunity against a number of diseases, and was recently proposed by the World Health Organization for human Ebola virus infection. Only a few small studies have so far been published on patients with COVID-19 and concomitant hematological malignancies (HM). The Italian Hematology Alliance on HM and COVID-19 has found that HM patients with COVID-19 clinically perform more poorly than those with either HM or COVID-19 alone. A COVID-19 infection in patients with B-cell lymphoma is associated with impaired generation of neutralizing antibody titers and lowered clearance of SARS-CoV-2. Treatment with CP was seen to increase antibody titers in all patients and to improve clinical response in 80% of patients examined. However, a recent study has reported impaired production of SARS-CoV-2-neutralizing antibodies in an immunosuppressed individual treated with CP, possibly supporting the notion of virus escape, particularly in immunocompromised individuals where prolonged viral replication occurs. This may limit the efficacy of CP treatment in at least some HM patients. More recently, it has been shown that CP may provide a neutralising effect against B.1.1.7 and other SARS-CoV-2 variants, thus expanding its application in clinical practice. More extensive studies are needed to further assess the use of CP in COVID-19-infected HM patients.

Keywords: COVID-19 antibodies; COVID-19 mutation; SARS-CoV-2; convalescent plasma preparations; hematological disorders; neutralising antibodies; plasmapheresis; prolonged viral shedding.

PubMed Disclaimer

Conflict of interest statement

The authors declare they have no conflicts of interest.

Figures

Figure 1
Figure 1
Indications for the use of convalescent plasma for COVID-19-infected subjects. (See References [15,31,38]).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323:1582–9. doi: 10.1001/jama.2020.4783. - DOI - PMC - PubMed
    1. Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest. 2020;130:1545–8. doi: 10.1172/JCI138003. - DOI - PMC - PubMed
    1. World Health Organization Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion as an empirical treatment during outbreaks. 2014:1–19. Available from: http://apps.who.int/iris/rest/bitstreams/604045/retrieve (accessed February 20, 2020).
    1. Burnouf T, Seghatchian J. Ebola virus convalescent blood products: where we are now and where we may need to go. Transfus Apher Sci. 2014;51:120–5. doi: 10.1016/j.transci.2014.10.003. - DOI - PMC - PubMed
    1. Seghatchian J, Lanza F. Convalescent plasma, an apheresis research project targeting and motivating the fully recovered COVID-19 patients: a rousing message of clinical benefit to both donors and recipients alike. Transfus Apher Sci. 2020;59 doi: 10.1016/j.transci.2020.102794. 102794. - DOI - PMC - PubMed